This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. Carrie Lee is a thoracic oncologist at the University of North Carolina Health in Chapel Hill, a Professor at UNC School of Medicine, and Director of the Thoracic Oncology Program at UNC Lineberger Comprehensive Cancer Center. Her clinical practice focuses on lung cancer and she has broad experience with traditional chemotherapy protocols as well as novel regimens.
Dr. Lee loves taking care of people. She has a passion for providing compassionate oncology care and says that when she treats patients, she approaches them as a whole person rather than as a statistic. She approaches each with attention to how the illness is impacting their day-to-day life as well as how it affects the other people in their lives.
Education and Career
Dr. Lee earned her medical degree at Northeast Ohio Medical University. After graduation, she completed her internship and Residency in Internal Medicine at the University of North Carolina Hospitals and never left. Following completion of her residency, she completed a fellowship in Hematology and Medical Oncology as well as a residency in Public Health and General Preventive Medicine.
Today, Dr. Lee is a professor in the Division of Hematology/Oncology, Medical Director of the UNC Lineberger Clinical Protocol Office, and Chief Medical Officer of UNC Lineberger Clinical Research, as well as of the Thoracic Oncology Program, Phase I Clinical Trials, and Clinical Trial Operations. She has been appointed chair of the Association of American Cancer Institute’s Clinical Research Initiative Steering Committee, which is responsible for developing better methods to disseminate information across cancer centers, identifying and addressing clinical research challenges and measuring progress on behalf of AACI. She is also a member of the American Society of Clinical Oncology.
Dr. Lee is passionate about advancing the science behind the development of new anti-cancer treatments. She says that the only way that cancer care can be made better for all patients is through clinical research, so over her years in medicine, she has developed and led clinical trials. She is now the Chief Medical Officer directing all clinical trials being conducted at UNC Lineberger Clinical Research and Medical Director of UNC Lineberger’s Clinical Protocol Office.
The research that Dr. Lee has conducted centers on care and outcomes of patients diagnosed with thoracic malignancies. Recent articles that she has authored or co-authored and that have been published in medical journals include:
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomized, phase 2 trial.Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13.PMID: 35033226
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.PMID: 25971938
Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015.PMID: 23438377 Review.
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes.
J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781.PMID: 27601549 No abstract available.
Curr Opin Oncol. 2006 Mar;18(2):162-72. doi: 10.1097/01.cco.0000208790.45312.25.PMID: 16462186 Review.
Clin Lung Cancer. 2006 May;7 Suppl 4:S111-7. doi: 10.3816/clc.2006.s.002.PMID: 16764751 Review.
Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA.Clin Lung Cancer. 2006 Nov;8(3):195-202. doi: 10.3816/CLC.2006.n.047.PMID: 17239295 Review.Get Your FREE Mesothelioma Packet
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.